Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Etoposide and TBI for ALL Stem Cell Transplant
NCT00427791Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2005
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2005; status: completed.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00427791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427791.